Media headlines about Lannett (NYSE:LCI) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lannett earned a news sentiment score of 0.00 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.1083037691679 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s analysis:
- EPS for Lannett Company, Inc. (LCI) Expected At $0.87; Mettler Toledo International (MTD) SI Increased By 21.42% – Hill Country Times (hillcountrytimes.com)
- Haeggquist & Eck Investigates Breach of Fiduciary Duties by Lannett Officers and Directors Related to Criminal … – Business Wire (press release) (businesswire.com)
- Haeggquist & Eck Investigates Breach of Fiduciary Duties by Lannett Officers and Directors Related to Criminal Investigation into Potential Price Collusion (finance.yahoo.com)
- Stocks Generating Improved Relative Strength: Lannett (finance.yahoo.com)
- Lannett Company, Inc. (LCI)- Major Healthcare stock of Recent Trade – Nasdaq Fortune (press release) (nasdaqfortune.com)
Several equities analysts recently weighed in on the stock. Oppenheimer reaffirmed a “hold” rating on shares of Lannett in a research note on Monday, December 11th. Zacks Investment Research raised shares of Lannett from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Friday, November 10th. ValuEngine cut shares of Lannett from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, BMO Capital Markets raised their target price on shares of Lannett from $20.00 to $22.00 and gave the company a “market perform” rating in a research note on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $23.60.
Lannett (NYSE:LCI) last posted its earnings results on Monday, November 6th. The company reported $0.60 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.08. The company had revenue of $155.00 million during the quarter, compared to analysts’ expectations of $153.62 million. Lannett had a net margin of 6.67% and a return on equity of 18.23%. Lannett’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period last year, the company posted $0.77 earnings per share. equities analysts predict that Lannett will post 3.04 EPS for the current fiscal year.
In other Lannett news, major shareholder David Farber sold 9,816 shares of Lannett stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $30.05, for a total value of $294,970.80. Following the completion of the transaction, the insider now directly owns 4,190,169 shares of the company’s stock, valued at approximately $125,914,578.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Arthur P. Bedrosian sold 7,422 shares of Lannett stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $25.20, for a total transaction of $187,034.40. Following the completion of the transaction, the chief executive officer now directly owns 679,001 shares of the company’s stock, valued at $17,110,825.20. The disclosure for this sale can be found here. Insiders sold a total of 130,000 shares of company stock valued at $3,430,991 over the last three months. Corporate insiders own 14.72% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2018/01/07/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-lannett-lci-stock-price.html.
Lannett Company Profile
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
What are top analysts saying about Lannett? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lannett and related companies.